GET DAILY SIGNALSIDEXX Laboratories (IDXX) Climbs +35% in 30 Days After Q3 Beat-and-Raise
Key Takeaways
- IDEXX Laboratories (IDXX) shares advanced roughly 35% over the trailing 30 days, rising from about $520 to around $703.
- The move was driven primarily by a third-quarter beat-and-raise: on November 2, 2026, the stock jumped roughly 22% in a single session after results topped estimates and full-year guidance was lifted.
- Third-quarter revenue rose 10% (reported and organic) to approximately $1.21 billion, with Companion Animal Group diagnostics recurring revenue up 11% organically.
- Management raised its 2026 revenue outlook to $4.741–$4.767 billion and its earnings-per-share outlook to $14.96–$15.16.
- Growth held up despite continued softness in U.S. veterinary clinic visits, supported by higher diagnostic usage per visit, new product adoption, and international expansion.
- For additional detail, explore IDEXX's Price Targets, Earnings, and Forecast pages on additional resources.
IDEXX Laboratories (IDXX) Company Overview and Market Position
IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation, developing and distributing diagnostic products and services primarily for the companion animal veterinary market, with additional offerings for livestock, poultry, dairy, and water testing. The company's core Companion Animal Group supplies in-clinic analyzers, rapid assays, and reference laboratory services, while its software portfolio includes practice management and diagnostic imaging systems.
IDEXX's business model is built on a large recurring revenue base. Once a veterinary clinic installs an IDEXX analyzer, it typically orders consumables and test kits for years, while reference laboratories generate ongoing testing volume. This "razor-and-blade" structure, combined with long-term trends in pet humanization and preventive care, has made IDXX a closely followed growth story in the healthcare sector. As a member of the S&P 500, the company is headquartered in Maine and serves customers across more than 170 countries. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
IDEXX Laboratories (IDXX) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, IDXX shares climbed from a closing level of approximately $520 in mid-October to roughly $703, a gain of about 35%. The bulk of the move occurred on November 2, 2026, when the stock surged nearly 22% in a single session following the company's third-quarter earnings release, closing at $671.64 before continuing higher in subsequent sessions.
The quarterly trend tells a similar story of a sharp re-rating. For much of the prior period, IDEXX shares traded under pressure as investors worried about declining U.S. veterinary clinic visits and the durability of growth in a price-sensitive pet-owning market. That cautious stance reversed decisively after the beat-and-raise, as the market repriced the stock to reflect the resilience of IDEXX's recurring diagnostics revenue even amid soft visit trends.
What Drove IDXX Stock Price in the Last 30 Days
The primary catalyst was IDEXX's third-quarter 2026 earnings report, released on November 2, 2026. The company posted revenue of about $1.21 billion, up 10% on both a reported and organic basis, exceeding analyst estimates near $1.19 billion. Comparable earnings per share came in at $3.96, ahead of consensus estimates in the $3.71–$3.72 range, while reported diluted EPS was $4.01, up 18% on a reported basis and 22% on a comparable basis.
Management also raised its full-year 2026 outlook, lifting the revenue range to $4.741–$4.767 billion and the earnings-per-share range to $14.96–$15.16. Companion Animal Group diagnostics recurring revenue grew 11% organically, with international regions up about 14% and the U.S. up about 10%. The company placed more than 1,900 inVue Dx analyzers during the quarter, bringing the installed base to nearly 11,000 instruments, and cited growth in its Cancer Dx and reference laboratory businesses. From what I see, the outsized reaction reflected positioning as much as fundamentals.
What Drove IDXX Stock Performance Over the Last Quarter
The broader multi-month narrative was one of skepticism giving way to validation. Entering the quarter, IDEXX shares had been weighed down by a roughly three-year trend of declining U.S. veterinary clinic visits, prompting concerns that softer pet-owner spending would pressure diagnostic volumes. The company's own disclosures showed same-store clinical visits declining an estimated 1.8% in the third quarter, underscoring the headwind.
What changed was the market's assessment of IDEXX's ability to grow despite that traffic weakness. The company demonstrated that expanding diagnostic usage per visit, a broadening test menu, premium instrument placements, and strong international performance could more than offset soft visit volumes. The September acquisition of CoVet, an AI-native ambient listening and clinical workflow platform, further signaled an expansion into software and AI-driven productivity tools for veterinary practices. This combination of durable recurring revenue and new growth avenues drove the stock's sharp quarterly advance.
IDXX Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching whether U.S. veterinary clinic visit trends stabilize or whether higher diagnostic utilization per visit continues to offset soft traffic. Progress on IDEXX's innovation pipeline, including the inVue Dx analyzer rollout and the expansion of its Cancer Dx panel, will be important indicators of future consumable pull-through. The integration of the CoVet acquisition and its contribution to software growth and diagnostic utilization is another area of focus.
Macroeconomic conditions also matter, given that pet-owner spending and currency movements can influence results. Competitive dynamics in pet diagnostics, instrument placement momentum, and margin progression will remain key watch points, as will any updates to full-year 2026 guidance and early signals around 2027. The company is scheduled to host an investor session at the VMX veterinary conference in January 2026 to showcase its next point-of-care analyzer, IDEXX MultiCue Dx. I'm watching this closely as these factors could shape the next phase of growth.
Exploring Tickeron’s Trending AI Robots
I often turn to Tickeron’s Trending AI Robots page when evaluating how algorithmic strategies are positioning around names like IDXX. It surfaces top-performing bots from hundreds of AI-driven options, each with different timeframes and metrics, giving a practical view of automated approaches without needing to review every strategy manually. This helps refine my thinking on market dynamics in a data-driven way.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
IDXX in +5.36% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IDXX advanced for three days, in 178 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 53 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 97 of 171 cases where IDXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. IDXX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.027) is normal, around the industry mean (67.298). P/E Ratio (47.242) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties
Advertisement